Cargando…

Utilization of the T2 Candida Panel for Rapid Candida Species Detection in a Large Community Hospital

BACKGROUND: Candidemia is the fourth leading hospital-acquired bloodstream infection. Blood cultures sensitivity is 50%. The T2 Candida Panel provide rapid (3–5 hours) species-specific detection of Candida species including C albicans, C. tropicalis, C. parapsilosis, C. krusei, and C. glabrata. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassoun, Ali, Abdulhaleem, Mohammed, Edwards, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630789/
http://dx.doi.org/10.1093/ofid/ofx163.1596
_version_ 1783269293413105664
author Hassoun, Ali
Abdulhaleem, Mohammed
Edwards, Jonathan
author_facet Hassoun, Ali
Abdulhaleem, Mohammed
Edwards, Jonathan
author_sort Hassoun, Ali
collection PubMed
description BACKGROUND: Candidemia is the fourth leading hospital-acquired bloodstream infection. Blood cultures sensitivity is 50%. The T2 Candida Panel provide rapid (3–5 hours) species-specific detection of Candida species including C albicans, C. tropicalis, C. parapsilosis, C. krusei, and C. glabrata. METHODS: Prospective, observational analysis included 345 patients who met specified criteria. The T2Candida Panel was restricted to Infectious Disease and Oncology physicians’ use for specific patient populations, including with: febrile neutropenia; ICU stay for >72 hours, central venous catheter, recent antibiotics, acute pancreatitis, recent major surgery, TPN, renal failure/hepatic failure, corticosteroids and unexplained fever. Antifungal use, patient characteristics, risk factors, T2 Candida Panel results, corresponding blood cultures, time to de-escalation, and duration of therapy (DOT) were collected. RESULTS: Patients mean age 60 years, 54% were male. Candidemia risk factors included: 28% immunocompromised (cancer, chemotherapy, chronic steroids, febrile neutropenia), 26% renal failure, 19% malnutrition/TPN, 14% CVC/PICC line and 11% intra-abdominal infection/surgery. 78% of the patients were in the ICU. 9% of T2 tests were positive. The resulting species were as follows: C. albicans/tropicalis, 47 % C. parapsilosis 41% and 12% C glabrata/Krusei. Of the patients with a positive T2 result only 24% had a positive corresponding blood culture while those with positive blood culture results 94.9% were T2 positive. Negative T2 tests resulted in discontinuation of antifungal therapy in 23% and avoid antifungal therapy initiation in 41% of patients but 36% of patient’s antifungal regimens were not discontinued despite a negative T2 result. Average time to de-escalation was 40.8 hours. Negative T2 results decreased average duration of therapy of micafungin by 2.1 days. CONCLUSION: T2 Candida Panel demonstrated greater sensitivity and faster to detect Candidemia compared with blood cultures. Despite the test’s rapid nature and high sensitivity, time to de-escalation remains at 2 days suggesting variations in physicians’ utilization of T2 test results. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-5630789
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56307892017-11-07 Utilization of the T2 Candida Panel for Rapid Candida Species Detection in a Large Community Hospital Hassoun, Ali Abdulhaleem, Mohammed Edwards, Jonathan Open Forum Infect Dis Abstracts BACKGROUND: Candidemia is the fourth leading hospital-acquired bloodstream infection. Blood cultures sensitivity is 50%. The T2 Candida Panel provide rapid (3–5 hours) species-specific detection of Candida species including C albicans, C. tropicalis, C. parapsilosis, C. krusei, and C. glabrata. METHODS: Prospective, observational analysis included 345 patients who met specified criteria. The T2Candida Panel was restricted to Infectious Disease and Oncology physicians’ use for specific patient populations, including with: febrile neutropenia; ICU stay for >72 hours, central venous catheter, recent antibiotics, acute pancreatitis, recent major surgery, TPN, renal failure/hepatic failure, corticosteroids and unexplained fever. Antifungal use, patient characteristics, risk factors, T2 Candida Panel results, corresponding blood cultures, time to de-escalation, and duration of therapy (DOT) were collected. RESULTS: Patients mean age 60 years, 54% were male. Candidemia risk factors included: 28% immunocompromised (cancer, chemotherapy, chronic steroids, febrile neutropenia), 26% renal failure, 19% malnutrition/TPN, 14% CVC/PICC line and 11% intra-abdominal infection/surgery. 78% of the patients were in the ICU. 9% of T2 tests were positive. The resulting species were as follows: C. albicans/tropicalis, 47 % C. parapsilosis 41% and 12% C glabrata/Krusei. Of the patients with a positive T2 result only 24% had a positive corresponding blood culture while those with positive blood culture results 94.9% were T2 positive. Negative T2 tests resulted in discontinuation of antifungal therapy in 23% and avoid antifungal therapy initiation in 41% of patients but 36% of patient’s antifungal regimens were not discontinued despite a negative T2 result. Average time to de-escalation was 40.8 hours. Negative T2 results decreased average duration of therapy of micafungin by 2.1 days. CONCLUSION: T2 Candida Panel demonstrated greater sensitivity and faster to detect Candidemia compared with blood cultures. Despite the test’s rapid nature and high sensitivity, time to de-escalation remains at 2 days suggesting variations in physicians’ utilization of T2 test results. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2017-10-04 /pmc/articles/PMC5630789/ http://dx.doi.org/10.1093/ofid/ofx163.1596 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Hassoun, Ali
Abdulhaleem, Mohammed
Edwards, Jonathan
Utilization of the T2 Candida Panel for Rapid Candida Species Detection in a Large Community Hospital
title Utilization of the T2 Candida Panel for Rapid Candida Species Detection in a Large Community Hospital
title_full Utilization of the T2 Candida Panel for Rapid Candida Species Detection in a Large Community Hospital
title_fullStr Utilization of the T2 Candida Panel for Rapid Candida Species Detection in a Large Community Hospital
title_full_unstemmed Utilization of the T2 Candida Panel for Rapid Candida Species Detection in a Large Community Hospital
title_short Utilization of the T2 Candida Panel for Rapid Candida Species Detection in a Large Community Hospital
title_sort utilization of the t2 candida panel for rapid candida species detection in a large community hospital
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630789/
http://dx.doi.org/10.1093/ofid/ofx163.1596
work_keys_str_mv AT hassounali utilizationofthet2candidapanelforrapidcandidaspeciesdetectioninalargecommunityhospital
AT abdulhaleemmohammed utilizationofthet2candidapanelforrapidcandidaspeciesdetectioninalargecommunityhospital
AT edwardsjonathan utilizationofthet2candidapanelforrapidcandidaspeciesdetectioninalargecommunityhospital